Hisamitsu Pharmaceutical Co., Inc. (TYO:4530)
4,437.00
+89.00 (2.05%)
May 2, 2025, 3:30 PM JST
TYO:4530 Balance Sheet
Financials in millions JPY. Fiscal year is March - February.
Millions JPY. Fiscal year is Mar - Feb.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2016 - 2020 |
---|---|---|---|---|---|---|
Period Ending | Feb '25 Feb 28, 2025 | Feb '24 Feb 29, 2024 | Feb '23 Feb 28, 2023 | Feb '22 Feb 28, 2022 | Feb '21 Feb 28, 2021 | 2016 - 2020 |
Cash & Equivalents | 114,518 | 112,459 | 122,154 | 129,290 | 114,254 | Upgrade
|
Short-Term Investments | 14,598 | 12,862 | 14,714 | 13,141 | 21,743 | Upgrade
|
Cash & Short-Term Investments | 129,116 | 125,321 | 136,868 | 142,431 | 135,997 | Upgrade
|
Cash Growth | 3.03% | -8.44% | -3.91% | 4.73% | -4.18% | Upgrade
|
Receivables | 46,879 | 42,983 | 39,753 | 38,112 | 39,203 | Upgrade
|
Inventory | 22,391 | 21,176 | 18,922 | 16,412 | 18,568 | Upgrade
|
Other Current Assets | 5,402 | 4,542 | 3,631 | 3,221 | 4,293 | Upgrade
|
Total Current Assets | 203,788 | 194,022 | 199,174 | 200,176 | 198,061 | Upgrade
|
Property, Plant & Equipment | 59,899 | 49,462 | 43,209 | 39,069 | 37,354 | Upgrade
|
Long-Term Investments | 71,494 | 76,813 | 69,244 | 61,133 | 62,220 | Upgrade
|
Goodwill | 1,294 | 1,444 | - | - | - | Upgrade
|
Other Intangible Assets | 4,680 | 5,387 | 946 | 1,326 | 1,178 | Upgrade
|
Long-Term Deferred Tax Assets | 1,911 | 1,649 | 1,342 | 1,153 | 1,047 | Upgrade
|
Other Long-Term Assets | 2 | 2 | 2 | 1 | 1 | Upgrade
|
Total Assets | 343,068 | 328,779 | 313,917 | 302,858 | 299,861 | Upgrade
|
Accounts Payable | 14,115 | 16,263 | 14,918 | 13,225 | 14,799 | Upgrade
|
Accrued Expenses | 2,213 | 1,831 | 1,340 | 1,363 | 1,350 | Upgrade
|
Short-Term Debt | 1,065 | 1,071 | 1,071 | 1,071 | 1,111 | Upgrade
|
Current Portion of Leases | 409 | 350 | 327 | 301 | 101 | Upgrade
|
Current Income Taxes Payable | 11,779 | 9,861 | 8,587 | 9,623 | 7,242 | Upgrade
|
Other Current Liabilities | 17,645 | 16,562 | 16,335 | 6,577 | 5,454 | Upgrade
|
Total Current Liabilities | 47,226 | 45,938 | 42,578 | 32,160 | 30,057 | Upgrade
|
Long-Term Debt | 1,694 | 76 | 147 | 219 | 296 | Upgrade
|
Long-Term Leases | 688 | 603 | 750 | 869 | 94 | Upgrade
|
Long-Term Deferred Tax Liabilities | 4,304 | 4,518 | 1,813 | 4,170 | 5,125 | Upgrade
|
Other Long-Term Liabilities | 1,932 | 1,967 | 1,815 | 2,339 | 2,553 | Upgrade
|
Total Liabilities | 63,663 | 61,700 | 55,511 | 47,973 | 46,053 | Upgrade
|
Common Stock | 8,473 | 8,473 | 8,473 | 8,473 | 8,473 | Upgrade
|
Additional Paid-In Capital | 2,361 | 2,361 | 2,361 | 2,356 | 2,352 | Upgrade
|
Retained Earnings | 257,881 | 242,578 | 235,569 | 236,192 | 233,376 | Upgrade
|
Treasury Stock | -47,550 | -36,993 | -27,196 | -19,527 | -11,495 | Upgrade
|
Comprehensive Income & Other | 55,659 | 48,455 | 37,157 | 25,674 | 19,592 | Upgrade
|
Total Common Equity | 276,824 | 264,874 | 256,364 | 253,168 | 252,298 | Upgrade
|
Minority Interest | 2,581 | 2,205 | 2,042 | 1,717 | 1,510 | Upgrade
|
Shareholders' Equity | 279,405 | 267,079 | 258,406 | 254,885 | 253,808 | Upgrade
|
Total Liabilities & Equity | 343,068 | 328,779 | 313,917 | 302,858 | 299,861 | Upgrade
|
Total Debt | 3,856 | 2,100 | 2,295 | 2,460 | 1,602 | Upgrade
|
Net Cash (Debt) | 125,260 | 123,221 | 134,573 | 139,971 | 134,395 | Upgrade
|
Net Cash Growth | 1.65% | -8.44% | -3.86% | 4.15% | -4.11% | Upgrade
|
Net Cash Per Share | 1699.18 | 1600.21 | 1694.75 | 1722.30 | 1643.25 | Upgrade
|
Filing Date Shares Outstanding | 72.96 | 75.74 | 77.77 | 79.74 | 81.76 | Upgrade
|
Total Common Shares Outstanding | 72.96 | 75.74 | 77.74 | 79.74 | 81.73 | Upgrade
|
Working Capital | 156,562 | 148,084 | 156,596 | 168,016 | 168,004 | Upgrade
|
Book Value Per Share | 3794.04 | 3497.00 | 3297.53 | 3175.01 | 3086.80 | Upgrade
|
Tangible Book Value | 270,850 | 258,043 | 255,418 | 251,842 | 251,120 | Upgrade
|
Tangible Book Value Per Share | 3712.17 | 3406.82 | 3285.36 | 3158.38 | 3072.39 | Upgrade
|
Updated Jan 9, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.